You have tucatinib, trastuzumab and capecitabine as cycles of treatment. This means you have the drugs and then a rest to allow your body to recover. Each cycle of treatment lasts 21 days (3 weeks).

Background: Trastuzumab (TZM) is available in IV (intravenous) and SC (subcutaneous) formulations in Morocco and is indicated for the treatment of patients with HER 2+ breast cancer. In Morocco, where ...

"Our findings show that subcutaneous administration was significantly faster than intravenous administration across all measured outcomes, including patient time in the treatment chair (primary ...

The subcutaneous trastuzumab originator has a fixed dosage of 600 mg. Almost all the participants were women (99.67%) with an average of 56.78 years old. Treatments were given across 73 hospitals in ...

Embracing Subcutaneous Drugs in Lung Cancer and Beyond — Patients by far prefer subcutaneous to intravenous medication delivery, says Jorge Nieva, MD by Greg Laub , Director, Video, MedPage ...

Subcutaneous pertuzumab (Perjeta) and trastuzumab (Herceptin) plus chemotherapy given in the neoadjuvant setting for patients with HER2-positive early breast cancer demonstrated similar efficacy and ...

Subcutaneous (SC) trastuzumab induced stromal tumor infiltrating lymphocyte (sTIL) enrichment and favorably varied immune parameters in patients with HER2-positive breast cancer with residual ...

Transcript: Chau T. Dang, MD: We use IV [intravenous] trastuzumab-pertuzumab during the chemotherapy phase because the patient already has a needle inserted, and it’s easy to continue delivering IV ...

One of the big life-changing things with being able to stay on Herceptin and Perjeta was I got to switch to Phesgo, which is the combination of Herceptin and Perjeta in a subcutaneous shot form. It's ...

Subcutaneous trastuzumab for HER2-positive, early-stage breast cancer was found to demonstrate a safety profile consistent with those reported in the primary analysis of the trial and with those ...

Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab was originally ...